Acetaminophen for self-reported sleep problems in an elderly population (ASLEEP): study protocol of a randomized placebo-controlled double-blind trial

  • Esther MM van de Glind1, 2Email author,

    Affiliated with

    • Lotty Hooft2,

      Affiliated with

      • Linda R Tulner3,

        Affiliated with

        • Joke HM Tulen4,

          Affiliated with

          • Ingeborg MJA Kuper3,

            Affiliated with

            • Hans L Hamburger5,

              Affiliated with

              • Sophia E de Rooij1 and

                Affiliated with

                • Barbara C van Munster1, 6

                  Affiliated with

                  Trials201415:10

                  DOI: 10.1186/1745-6215-15-10

                  Received: 30 November 2012

                  Accepted: 13 December 2013

                  Published: 7 January 2014

                  Abstract

                  Background

                  The prevalence of sleep disorders increases with age. Sleep disorders may have serious health implications and may be related to serious underlying diseases. Many older people use hypnotics, like benzodiazepines, although these medications have serious side effects and often lead to habituation. Acetaminophen is one of the most frequently used off-label drugs for sleep disorders, although little is known about its effects. Our objective is to investigate whether acetaminophen is effective in treating self-reported sleep disorders in older people.

                  Methods/Design

                  Participants, aged 65 years or older (n = 150), who have sleep disorders will be randomized for treatment with either acetaminophen 1000 mg or placebo, once daily at bedtime in a double-blind design. Eligible patients should be able to give informed consent, should not be cognitively impaired (Minimal Mental State Examination (MMSE) score ≥ 20), should not have pain, and should not use acetaminophen on a regular basis because of pain complaints. The study will take three weeks to complete. During these three weeks, the participants register their sleep behavior in a sleep diary. The participants will use the study medication during the second and third week. The primary endpoint will be the self-reported sleep disorders at the end of week three, as measured by means of the Insomnia Severity Index (ISI). To validate these subjective sleep parameters against objectively measured indices of the sleep-wake pattern, we will measure the periods of wakefulness and sleep in a subgroup of participants, using an actigraph worn on the wrist during the entire study period.

                  Discussion

                  The proposed study will contribute to our knowledge about the treatment of sleep disorders in an older population. There is a need for treatments for sleep disorders without serious adverse effects. Acetaminophen might be a simple and inexpensive alternative for the regimes that are currently used with older people.

                  Trial registration

                  The Netherlands National Trial Register NTR2747.

                  Keywords

                  Acetaminophen Geriatrics Protocol RCT Sleep

                  Background

                  The prevalence of sleep disorders is high in older subjects. In the Established Populations for Epidemiologic Studies of the Elderly (EPESE) study, involving 9,282 community-dwelling persons aged 65 and older, 50% reported sleep complaints, of which 25% had insomnia [1]. In a study of older patients in 11 primary care practices (n = 1503), the most commonly reported sleep-related complaints were difficulty sleeping (45%), snoring (33.3%), and excessive daytime sleepiness (27.1%) [2]. Subjects with insomnia report a negative impact on quality of life [3].

                  There are various hypotheses as to why older persons suffer from sleep disorders. Single or multiple medical problems, such as depression, cardiovascular diseases, and pulmonary problems can interfere with a good night’s rest. In addition, older people often use medication that causes insomnia, for example beta blockers and psychopharmacological drugs. Only a minority of older people suffer from primary insomnia [4].

                  The best treatment for sleep disorders remains a topic of discussion. There is evidence for a positive effect of cognitive behavioral interventions for sleep disorders in older people [5, 6], but these are time-consuming and dependent on patient motivation. Some authors state that bright light therapy might help, especially in the case of a dysregulation of the circadian rhythm, but as yet there have been no randomized trials [7]. There is a lack of evidence from well-designed trials of the effectiveness of physical exercise for the treatment of sleep problems in healthy older people [8]. The most common way of treating sleep disorders is the pharmacological approach [9]. Many older people use a sedative benzodiazepine as a hypnotic, although they are at risk of harmful side effects because of age-related pharmacodynamic and pharmacokinetic changes [10]. Adverse events, such as falling [11, 12], cognitive impairment [13], and drug dependence [14], and even an increased risk of death [15] are reported. Considering the health impact, the complexity and the high prevalence, sleep disorders are an important area of investigation and simple treatments with fewer side effects are urgently needed.

                  In geriatric clinical practice, we have noticed that older patients use acetaminophen for sleep problems without having underlying pain complaints. In a survey of 176 older people, 48% stated that they used nonprescription products for sleeping problems. Of the individuals who had used a nonprescription product, 19% used acetaminophen [16]. Although we did not find any trials or observational studies in the literature that report the effect of acetaminophen on sleep disorders, there are some ideas as to why this medication might have a positive effect. People who sleep better on acetaminophen may have unrecognized pain complaints. Another possible hypothesis is that acetaminophen, after metabolization in the brain, reinforces the activity of the cannabinoid receptors, which in turn reinforce the activity of the serotonergic system [17, 18]. Also, there may be a relationship with body temperature [19], or its purported effect could be mainly placebo.

                  This paper describes the design of the study named ASLEEP (Acetaminophen for SLEep Problems in Elderly Patients), a trial currently in progress. The aim of this trial is to investigate whether acetaminophen has an effect on self-reported sleep disorders in older people, as measured by a score on a validated sleep questionnaire, the Insomnia Severity Index (ISI) [20]. Also, to validate the subjective sleep parameters against objectively measured indices of the sleep-wake pattern, we aim to study the effects of acetaminophen on periods of wakefulness and sleep, as measured by actigraphy in a subgroup of our participants [21].

                  Methods/Design

                  This study is a randomized, placebo-controlled, double-blind, national, multicenter study with a duration of three weeks. This study will be carried out in three teaching hospitals in the Netherlands: the Academic Medical Center, the Gelre Hospitals, and the Slotervaart Hospital. The study population will consist of people aged 65 years and older suffering from sleep disorders, defined as one or more of the following symptoms: difficulty falling asleep, difficulty maintaining sleep or early awakenings without being able to fall asleep again, with a frequency of at least three nights a week, during at least three consecutive weeks [22]. Participants may be patients that visit one of the participating hospitals’ outpatient clinics, or they may be subjects who are recruited after advertising in local newspapers. The visitors of the outpatient clinic will be enrolled during their visit; the people who respond to the advertisements will be invited to come to one of the participating hospitals for enrollment.

                  Eligible patients should have a score of five points or more on the Pittsburgh Sleep Quality Index (PSQI) [23]. This is a validated instrument that assesses sleep quality and disturbances over a 1-month time interval. A global PSQI score greater than 5 yielded a diagnostic sensitivity of 89.6% and specificity of 86.5% in distinguishing good and poor sleepers [23]. Further inclusion criteria are: a score of 20 points or more on the Minimal Mental State Examination (MMSE) [24] and participants must be willing and medically able to receive therapy according to the protocol for the duration of the study. In addition, participants must be able to give informed consent themselves.

                  Exclusion criteria are the inability to speak, understand or write Dutch; the inability to follow the study procedures, as assessed by the researcher; alcohol intake of more than four units daily; the concomitant use of acetaminophen (>1000 mg daily); pain complaints resulting in a pain score of 6 or higher on a visual analog scale; impaired liver function; suicidal tendencies; and participation in other sleep trials. In addition, patients with a life expectancy of less than three months, according to the attending physician, or with a sleep problem due to a medical or somatic reason (a suspicion of obstructive sleep apnea syndrome, restless legs, delirium, or a depression necessitating antidepressants) are excluded.

                  Demographic data, medical history, and medication use are recorded at baseline. The cognitive status is assessed with the MMSE [24] and functional status is assessed with the Katz-15 Activities of Daily Living index [25]. The severity and number of comorbidities is scored with the Charlson comorbidity index [26]. Possible confounding factors, like the use of comedication, other sleeping pills, and the use of alcohol and coffee are registered for all patients.

                  During the first week, participants only register their sleep patterns. In the second and third weeks, they also take either 1000 mg acetaminophen in two tablets of 500 mg each, or two tablets of an exact matching placebo, once per day at bedtime. Study medication is packaged in small bottles labeled according to Good Manufacturing Procedure guidelines. The medication is provided in sequentially numbered containers according to the randomization list. In the sleep diary, patients register if they had taken the study medication the night before.

                  Participants are allowed to continue their own prescriptions, including their sleeping pills. They are asked not to use newly prescribed sleeping pills. However, sometimes it may happen that participants feel they cannot sleep without using a sleeping pill in addition to the study medication. If this happens, they are asked to register this in the sleep dairy. Should it happen that patients unexpectedly start a sleeping pill, they will no longer receive the study medication, but data collection will be continued.

                  Participants who need acetaminophen as a painkiller during the study period will be prescribed this as usual and will no longer receive the study medication. However, use of acetaminophen and not being able to stop this medication during the study period is a reason for exclusion. Also, patients who use acetaminophen as a sleeping pill are asked to stop the medication for the 3-week study period, that is, both for the baseline data collection and for the period that they use the study medication. In the case of an unexpected need for acetaminophen, despite the precautions taken in the enrollment procedure, participants should stop using the study medication, because of a risk of overdose. However, the data collection will be continued in these cases and we will perform both an intention-to-treat and a per-protocol analysis.

                  The primary outcome measure will be the difference in score on the ISI [6, 27], as completed at the end of the first and third weeks. Secondary outcomes will be the use of extra sleeping pills and objective sleep parameters, registered by means of an Actiwatch [21, 28]. The Actiwatch is a wristwatch-like device, worn on the nondominant hand, which records the motion for each epoch (typically 30 to 60 seconds) for several weeks. A subgroup of 25 patients enrolled in the Slotervaart Hospital will wear the Actiwatch for 24 hours a day during the three-week study period. In our trial, the Actiwatch Spectrum device (Philips Respironics) will be used. Movements are recorded in 1-minute epochs. The raw activity scores will be translated to sleep-wake scores for each epoch, based on standard algorithms, which are part of the proprietary software that will be used to analyze the data. In addition to this, all participants will record in a sleep diary the time they get into and out of bed, the estimated time they fall asleep and wake up in the morning and the number of awakenings during the night. Furthermore, patients will register a daily pain score by means of a 10 cm visual analog scale. In addition, they will rate their sleep quality with a score of 0 to 10. The combination of the actigraphy data and the sleep diary will be used to estimate the following sleeping and waking endpoints: total sleep time (minutes sleep between bedtime and waking time), sleep efficiency (percentage of time asleep while in bed), sleep onset latency (minutes between bedtime and the first block of consistent sleep scored epochs after bedtime), time awake after sleep onset (minutes awake between sleep onset and waking time), number of long wakeful episodes and number of daytime nap episodes [21]. The Actiwatch Spectrum has an ‘off wrist detection’ feature that will be used to exclude daytime data if the participant takes the actigraph off for more than 10% of the wake period [29].

                  The risks associated with this study consist of the possible adverse effects of acetaminophen. This is widely used as an analgesic and has proved to be effective and safe; therefore, the occurrence of side effects is not likely. However, all adverse effects will be registered according to Good Clinical Practice guidelines. During the study, patients will be contacted by phone to evaluate possible side effects.

                  An independent statistician provided a computer-generalized randomization list, using block randomization of ten participants per block. This list was stratified by study center. The trial-pharmacist is the only one in possession of the randomization list. The researcher who enrolled the patients is not aware of the assignment of the participants. Subject enrollment started on 1 July 2011.

                  This study will be carried out in compliance with the Helsinki Declaration. The Medical Ethics Committee of the Academic Medical Center has approved the study design, protocol, and informed consent procedures. The executive boards of the other participating centers, the Slotervaart Hospital and Gelre Hospitals, have provided local feasibility approval.

                  Power analysis

                  The primary endpoint will be a reduction in subjective sleep disorders, as reflected in a lower score on the ISI at the end of the third week compared with the score after the first week. From the literature, a prevalence of sleep disorders of 30% to 50% is reported. Group sample sizes of 75 per group achieve 80% power to detect a difference of three points on the ISI between the null hypothesis that both group mean differences are zero and the alternative hypothesis that the mean difference of the intervention group is three, with an assumed group standard deviations of 6.5. This calculation is based on data from a study in which a group of patients with insomnia were treated with either eszopiclone or placebo [30].

                  Statistics

                  Data will be primarily analyzed according to the intention-to-treat principle. The outcome measures will be tested by using t tests and Mann–Whitney tests for continuous variables and by using chi-squared tests for categorical outcomes. The data from the actigraphy and the sleep diary will be analyzed as continuous variables, either with an independent t test or with a Wilcoxon rank-sum test. We will perform a subgroup analysis for patients using sleeping pills at baseline and those who do not. If needed, we will adjust for the use of add-on sleeping pills. Analyses will be performed with the program Statistical Package for the Social Sciences (SPSS) version 18.

                  Discussion

                  Sleep disorders are a major problem in older people, and are associated with comorbidities and high costs. To achieve good external validity, we intend to include patients with all comorbidities and applied minimal exclusion criteria. Older patients are often excluded from clinical trials [31, 32]. An additional benefit of this research, which focuses on older patients, may be an insight into the challenges and methods for performing research with older patients. The proposed study will contribute to our knowledge about the treatment of sleep disorders in an older population by providing an alternative for the traditional hypnotics. There is a need for treatments for sleep disorders without serious adverse effects. Acetaminophen could potentially fill this gap, as it may be a promising simple and cheap alternative for regimes that are currently used with older people.

                  Trial status

                  The ASLEEP trial is currently in progress; patient recruitment started on 1 July 2011 and was finished in July 2013.

                  Abbreviations

                  ASLEEP: 

                  Acetaminophen for SLEep Problems in Elderly Patients

                  EPESE: 

                  Established populations for epidemiologic studies of the elderly

                  ISI: 

                  Insomnia severity index

                  MMSE: 

                  Minimal mental state examination

                  PSQI: 

                  Pittsburgh sleep quality index.

                  Declarations

                  Acknowledgements

                  Edi Niezink and Susan van Ginkel contributed to the data collection. Stephanie Medlock performed a spelling and grammar check.

                  This research was conducted in fulfillment of a PhD by Esther van de Glind. Further support was provided by a grant for the ICOVE (#311020302) project from the Netherlands Organisation for Health Research and Development. Actigraphs have been financed by Philips. The Netherlands Organisation for Scientific Research provided funding for the payment of the open access fee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

                  Authors’ Affiliations

                  (1)
                  Department of Internal Medicine, Geriatrics Section, Academic Medical Center
                  (2)
                  Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam
                  (3)
                  Department of Geriatric Medicine, Slotervaart Hospital
                  (4)
                  Department of Psychiatry, Erasmus MC
                  (5)
                  Department of Clinical Neurophysiology and Amsterdam Center for Sleep-Wake Disorders, Slotervaart Hospital
                  (6)
                  Department of Geriatric Medicine, Gelre Hospitals

                  References

                  1. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG: Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995,18(6):425–432.PubMed
                  2. Reid KJ, Martinovich Z, Finkel S, Statsinger J, Golden R, Harter K, Zee PC: Sleep: a marker of physical and mental health in the elderly. Am J Geriatr Psychiatry 2006,14(10):860–866.PubMedView Article
                  3. Roth T, Ancoli-Israel S: Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999,22(Suppl 2):S354-S358.
                  4. Ancoli-Israel S: Sleep and its disorders in aging populations. Sleep Med 2009,10(Suppl 1):S7-S11.PubMedView Article
                  5. Montgomery P, Dennis J: Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003, 1:CD003161.PubMed
                  6. Morin CM, Benca R: Chronic insomnia. Lancet 2012,379(9821):1129–1141.PubMedView Article
                  7. Montgomery P, Dennis J: Bright light therapy for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2002, 2:CD003403.PubMed
                  8. Montgomery P, Dennis J: Physical exercise for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2002, 4:CD003404.PubMed
                  9. Kupfer DJ, Reynolds CF III: Management of insomnia. N Engl J Med 1997,336(5):341–346.PubMedView Article
                  10. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS: Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005,6(2):107–113.PubMedView Article
                  11. Nurmi-Lüthje I, Kaukonen JP, Lüthje P, Naboulsi H, Tanninen S, Kataja M, Kallio ML, Leppilampi M: Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging 2006,23(1):27–37.PubMedView Article
                  12. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM: Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999,47(7):850–853.PubMed
                  13. Stewart SA: The effects of benzodiazepines on cognition. J Clin Psychiatry 2005,66(Suppl 2):9–13.PubMed
                  14. O’Brien CP: Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005,66(Suppl 2):28–33.PubMed
                  15. Kripke DF, Langer RD, Kline LE: Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open 2012,2(1):e000850.PubMed CentralPubMedView Article
                  16. Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S: The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 1999,14(10):851–857.PubMedView Article
                  17. Courade JP, Caussade F, Martin K, Besse D, Delchambre C, Hanoun N, Hamon M, Eschalier A, Cloarec A: Effects of acetaminophen on monoaminergic systems in the rat central nervous system. Naunyn Schmiedebergs Arch Pharmacol 2001,364(6):534–537.PubMedView Article
                  18. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, Libert F, Eschalier A: Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008,139(1):190–200.PubMedView Article
                  19. Lack LC, Gradisar M, van Someren EJ, Wright HR, Lushington K: The relationship between insomnia and body temperatures. Sleep Med Rev 2008,12(4):307–317.PubMedView Article
                  20. Bastien CH, Vallieres A, Morin CM: Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001,2(4):297–307.PubMedView Article
                  21. Sadeh A: The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev 2011, 15:259–267.PubMedView Article
                  22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Health Disorders. Washington DC; 2000. [4th edition, text revision]
                  23. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989,28(2):193–213.PubMedView Article
                  24. Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975,12(3):189–198.PubMedView Article
                  25. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged. The index of ADL: a standardized measurement of biological and psychosocial function. JAMA 1963, 185:914–919.PubMedView Article
                  26. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987,40(5):373–383.PubMedView Article
                  27. Morin CM: Insomnia. New York: Psychological assessment and management; 1993.
                  28. Hoekert M, der Lek RF, Swaab DF, Kaufer D, van Someren EJ: Comparison between informant-observed and actigraphic assessments of sleep-wake rhythm disturbances in demented residents of homes for the elderly. Am J Geriatr Psychiatry 2006,14(2):104–111.PubMedView Article
                  29. Maglione JE, Ancoli-Israel S, Peters KW, Paudel ML, Yaffe K, Ensrud KE, Stone KL: Depressive symptoms and subjective and objective sleep in community-dwelling older women. J Am Geriatr Soc 2012,60(4):635–643.PubMed CentralPubMedView Article
                  30. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T: Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007,30(8):959–968.PubMed
                  31. Mody L, Miller DK, McGloin JM, Freeman M, Marcantonio ER, Magaziner J, Studenski S: Recruitment and retention of older adults in aging research. J Am Geriatr Soc 2008,56(12):2340–2348.PubMed CentralPubMedView Article
                  32. Harris R, Dyson E: Recruitment of frail older people to research: lessons learned through experience. J Adv Nurs 2001, 36:643–651.PubMedView Article

                  Copyright

                  © van de Glind et al.; licensee BioMed Central Ltd. 2014

                  This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.